Showing results (121-130 of 928) with videos related to
Sort By:
Pageof 93
Pain|November 6, 2021
Who are the placebo responders? A cross-sectional cohort study for psychological determinantsYang Wang, Esther Chan, Susan G Dorsey, et al.Psychopharmacology|August 19, 2019
Classical conditioning of antidepressant placebo effects in miceSamuel R Krimmel, Panos Zanos, Polymnia Georgiou, et al.European Journal of Pain (London, England)|July 3, 2024
Nocebo belief and attitudes towards side effect disclosure: A general population-based online survey in Europe and North AmericaMette Sieg, Kelly S Clemens, Luana Colloca, et al.Journal of Clinical Nursing|February 2, 2019
Contextual factors triggering placebo and nocebo effects in nursing practice: Findings from a national cross-sectional studyAlvisa Palese, Lucia Cadorin, Marco Testa, et al.Journal of Clinical Pharmacology|February 23, 2016
Response Surface Analysis and Nonlinear Optimization Algorithm for Maximization of Clinical Drug Performance: Application to Extended-Release and Long-Acting Injectable PaliperidoneRoberto Gomeni, Françoise Bressolle-Gomeni, Maurizio FavaThe World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|March 12, 2010
Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorderGeorge I Papakostas, Dana Charles, Maurizio FavaThe Psychiatric Clinics of North America|March 17, 2007
A critical overview of the pharmacologic management of treatment-resistant depressionAndrew A Nierenberg, Judith Katz, Maurizio FavaTranslational Psychiatry|April 29, 2023
Artificial intelligence approach for the analysis of placebo-controlled clinical trials in major depressive disorders accounting for individual propensity to respond to placeboRoberto Gomeni, Françoise Bressolle-Gomeni, Maurizio FavaJournal of Clinical Pharmacology|January 27, 2018
Is It Time for Going Beyond the P-Value Paradigm With the Estimation of the Probability of Clinical Benefit as a Criterion for Assessing the Outcomes of a Clinical Trial? A Case Study in Patients With Major Depressive DisorderRoberto Gomeni, Françoise Bressolle-Gomeni, Maurizio FavaMolecular Psychiatry|June 25, 2026
Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventionsClotilde Guidetti, Maurizio Fava, George I PapakostasPageof 93